Gt Biopharma Inc (GTBP)

01:00 AM

Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily

01:00 AM

Feb 06, 2025

GT Biopharma Announces Recently Presented Data on Our Next Generation TriKE (OXS-C3550) at The Ash Meeting in Atlanta, GA - ACCESS Newswire

Feb 06, 2025

Feb 05, 2025

Nanobodies Market Analysis: Growth Drivers in Targeted - openPR

Feb 05, 2025

Feb 04, 2025

Pre-market Movers In Healthcare Sector: HUGE, ONTX, SVRA, CELC, CHFS... - RTTNews

Feb 04, 2025

Jan 29, 2025

StockNews.com Initiates Coverage on Beasley Broadcast Group (NASDAQ:BBGI) - Defense World

Jan 29, 2025

Jan 29, 2025

StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS) - Defense World

Jan 29, 2025

Jan 29, 2025

Barnes Group (NYSE:B) Now Covered by StockNews.com - Defense World

Jan 29, 2025

Jan 29, 2025

Apollo Commercial Real Estate Finance (NYSE:ARI) Stock Rating Lowered by StockNews.com - Defense World

Jan 29, 2025

Jan 29, 2025

First Financial Bancorp Reports Solid Financial Performance in Fourth Quarter 2024 - Defense World

Jan 29, 2025

Jan 29, 2025

StockNews.com Begins Coverage on Power REIT (NYSE:PW) - Defense World

Jan 29, 2025

Jan 29, 2025

Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com - Defense World

Jan 29, 2025

Jan 29, 2025

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded by StockNews.com to Hold Rating - Defense World

Jan 29, 2025

Jan 29, 2025

Goldman Sachs Announces Adoption of Tax Benefit Preservation Plan - Defense World

Jan 29, 2025

Jan 29, 2025

Seaport Res Ptn Forecasts Weaker Earnings for Sands China - Defense World

Jan 29, 2025

Jan 29, 2025

Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World

Jan 29, 2025

Jan 29, 2025

Cormark Weighs in on Real Matters’ FY2025 Earnings (TSE:REA) - Defense World

Jan 29, 2025

Jan 29, 2025

AmpliTech Group, Inc. (NASDAQ:AMPG) Short Interest Down 60.9% in January - Defense World

Jan 29, 2025

Jan 28, 2025

GT Biopharma Announces First Patient Dosed in Phase 1 Trial - GlobeNewswire

Jan 28, 2025

Jan 27, 2025

GT Biopharma, Inc. Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies - Marketscreener.com

Jan 27, 2025

Jan 27, 2025

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies - The Manila Times

Jan 27, 2025

Jan 27, 2025

GT Biopharma Initiates Phase 1 Trial of Advanced TriKE Therapy for Blood Cancers - StockTitan

Jan 27, 2025

Jan 25, 2025

GT Biopharma and Cytovance Biologics Announce Collaboration Agreement TriKE(TM) Therapeutic for Treatment of Coronavirus Infection - ACCESS Newswire

Jan 25, 2025

Jan 16, 2025

Nanobodies Market Generated Opportunities, Future Scope - openPR

Jan 16, 2025

Jan 14, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Jan 14, 2025

Jan 13, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Jan 13, 2025

Jan 13, 2025

Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews

Jan 13, 2025

Jan 08, 2025

Nanobodies Market reached US$ 502.60 million in 2023 and - openPR

Jan 08, 2025

Jan 01, 2025

Biotech Stocks Surging in September - AccessWire

Jan 01, 2025

Dec 26, 2024

Maryland Biotech Gains Regulatory Approval - Streetwise Reports

Dec 26, 2024

Dec 24, 2024

GT Biopharma files automatic mixed securities shelf - MSN

Dec 24, 2024

Dec 24, 2024

FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace

Dec 24, 2024

Dec 23, 2024

Stock market today: Traws Pharma +231.47%, Rumble +59.02% among top gainers in early trading - Business Upturn

Dec 23, 2024

Dec 23, 2024

First Heartland Consultants Inc. Sells 10,222 Shares of Amazon.com, Inc. (NASDAQ:AMZN) - Defense World

Dec 23, 2024

Dec 20, 2024

Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeut - Barchart

Dec 20, 2024

Dec 19, 2024

GTBP Stock Hits 52-Week Low at $1.92 Amid Market Challenges - Investing.com

Dec 19, 2024

Dec 17, 2024

New Data Supports BLA Package - Streetwise Reports

Dec 17, 2024

Dec 15, 2024

Contrasting GT Biopharma (NASDAQ:GTBP) and Allakos (NASDAQ:ALLK) - Defense World

Dec 15, 2024

Dec 13, 2024

The Goodyear Tire & Rubber Company (NASDAQ:GT) Shares Acquired by Fmr LLC - Defense World

Dec 13, 2024

Dec 11, 2024

BeautyHealth Releases 2024 Skintuition Report - Quantisnow

Dec 11, 2024

Dec 10, 2024

Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says - Streetwise Reports

Dec 10, 2024

Dec 09, 2024

California Biopharma Shows Promising Phase 1 Data - Streetwise Reports

Dec 09, 2024

Dec 09, 2024

Nanobodies Market Is Booming Worldwide 2024-2031 | Merck KGaA, - openPR

Dec 09, 2024

Dec 06, 2024

Drug Trial Shows Positive Interim Results for ALS Treatment - Streetwise Reports

Dec 06, 2024

Dec 06, 2024

FDA Decision on Drug for Bone Marrow Due Early 2025 - Streetwise Reports

Dec 06, 2024

Dec 05, 2024

Roth Capital Weighs in on GT Biopharma FY2024 Earnings - Defense World

Dec 05, 2024

Dec 05, 2024

United States Nanobodies Market Size, Trends, Growth, - openPR

Dec 05, 2024